NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Toxys

Toxys

Private
OegstgeestHealthcare & Life Scienceshttps://toxys.com

Last Round

Grant

Dec 17, 2024

Total Funding Raised

$3.54M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Toxys is a biotechnology company that provides innovative in vitro toxicity screening solutions to identify hazardous properties of novel compounds for the pharmaceutical, chemical, cosmetics, and food industries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Compliance & Risk

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales, Data as a Service, Government Contracts

AI Layer

Non-AI

Keywords

in vitro toxicologyanimal-free testinggenotoxicity assaymechanistic toxicologycontract research organizationCROToxTrackerpredictive toxicologyalternative to animal testingpreclinical toxicologyNew Approach MethodologiesNAMsstem cell-based assayreporter cell linesafety assessmenttoxicology assay kitdevelopmental toxicityReproTrackerDNA damage analysis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Toxys Comparables

Compare Toxys with similar companies based on industry and business-model similarity.

Toxys comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Scantox Group
83%
intoDNA
77%
Emulate
74%

Toxys Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 17, 2024
Early FundingMar 10, 2020
GrantSep 21, 2016
Series AFeb 18, 2016

Key People

Founding team and executive leadership

Giel Hendriks

CEO

Executive Team

Remco Derr

Chief Operating Officer

Executive Team

Toxys Investors

Notable investors and investment history

Toxys investors
InvestorRounds
NC3RsGrant
EIT HealthGrant
KIKK CapitalEarly Funding
InnovationQuarterSeries A, Early Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 24, 2026

    Signed an MoU with the Korean Institute of Toxicology (KIT).

Toxys Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Toxys Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Toxys's valuation, stock price, and market status.

Firmographic Details

HeadquartersOegstgeest
Employee Range38
Year Founded2014
Last FundingDec 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.